FIELD: medicine.
SUBSTANCE: there is offered application of antagonist of angiotensin (II) (ATP) type 1 receptor or its pharmaceutically acceptable salt, particularly Candesartan, Candesartan cylexetyl, Losartan, Valsartan, Irbesartan, Ta-sosartan, Telmisartan and Eprosartan for making a medical product for prevention of stroke, or for making a medical product for prevention of diabetes, or for making a medical product for prevention of congestive heart failure (CHF) in the patient with high risk of cardiovascular attack in view of the previous history of coronary heart disease, stroke or peripheral arterial disease.
EFFECT: there is shown apparent reduction of number of patients with developed stroke, diabetes or CHF, thus in the beginning of study, the patients had normal or lowered blood pressure and no CHF signs.
9 cl, 1 ex
